Daiichi Sankyo US

Daiichi Sankyo, Inc. is a leading global pharmaceutical company with a significant presence in the United States, committed to creating innovative medicines that meet unmet medical needs. Established in the U.S. in 2005, Daiichi Sankyo leverages over 120 years of heritage and expertise in the field of medicine, particularly focusing on oncology treatments. The company is renowned for its advanced expertise in drug development, which is evident in its research into antibody-drug conjugates designed to target and treat various forms of cancer. At Daiichi Sankyo, the philosophy revolves around passion for innovation and compassion for patients, driving a mission that turns hope into reality for those battling illnesses.

In addition to its focus on oncology, Daiichi Sankyo is dedicated to improving treatment for cardiovascular diseases and other therapeutic areas with high unmet medical needs. The company collaborates with healthcare professionals and organizations to ensure that its innovative therapies are accessible to patients globally. As of now, Daiichi Sankyo operates in more than 30 countries, aiming to discover, develop, and deliver cutting-edge healthcare solutions while prioritizing patient care and public health. The corporate culture emphasizes scientific collaboration, integrity, and accountability, shaping a workplace that nurtures talent and fosters continuous learning and growth.